JamesHTonsgardMD

Neurology • Chicago, IL

Associate Professor of Pediatrics and Neurology, University of Chicago Medicine

Join to view full profile

Dr. Tonsgard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tonsgard's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-702-4786

Education & Training

University of ChicagoResidency, Neurology, 1977 - 1981
Yale-New Haven Medical CenterResidency, Pediatrics, 1975 - 1977
Yale School of MedicineClass of 1975

Certifications & Licensure

IL State Medical License 1977 - 2026
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Chicago Magazine: Top Doctors Castle Connolly, 2012, 2014

Clinical Trials

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Start of enrollment: 2009 Jul 01
Completed
Phase 2
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10
Completed
Phase 2
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Start of enrollment: 2013 May 15
Completed
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01
Completed
Phase 2
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) Start of enrollment: 2015 Nov 13
Recruiting
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

307 citations
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Eric Legius, Ludwine Messiaen, Pierre Wolkenstein, P Pancza, Robert A. Avery
Genetics in Medicine. 2021-05-19
46 citations
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexifor...
Brian Weiss, Pamela L. Wolters, Scott R. Plotkin, Brigitte C. Widemann, James H. Tonsgard
Journal of Clinical Oncology. 2021-01-28
96 citations
Sirolimus for progressive neurofibromatosis type 1–associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
Brian Weiss, Brigitte C. Widemann, Pamela L. Wolters, Eva Dombi, Alexander A. Vinks
Neuro-Oncology. 2015-04-01

Grant Support

The Role Of Dicarboxylic Acids In Reye'S SyndromeNational Institute Of Neurological Disorders And Stroke1986–1988